H.C. Wainwright Upgrades Structure Therapeutics (GPCR) on Massive Arbitrage Opportunity for Oral GLP-1

Key Highlights

• On December 19, H. C.
• Wainwright analyst Ananda Ghosh raised the firm’s price target on Structure Therapeutics to $90 from $60 with a Buy rating on the shares.
• The firm suggested that the company’s titration strategy has been validated by key opinion leaders.
• As payer economics push oral GLP-1s toward Tier 1 therapy status, H. C.
• Wainwright views Structure Therapeutics’ current valuation as a significant arbitrage opportunity when compared to recent industry deal metrics.